×
CorMedix Inc EBIT 2011-2025 | CRMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
CorMedix Inc ebit from 2011 to 2025. Ebit can be defined as earnings before interest and taxes.
View More
CorMedix Inc EBIT 2011-2025 | CRMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
CorMedix Inc ebit from 2011 to 2025. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$222.7B
Amgen (AMGN)
$161.5B
Gilead Sciences (GILD)
$142.5B
Vertex Pharmaceuticals (VRTX)
$123.1B
Bristol Myers Squibb (BMY)
$98.7B
GSK (GSK)
$81B
CSL (CSLLY)
$78.2B
Regeneron Pharmaceuticals (REGN)
$60.4B
Alnylam Pharmaceuticals (ALNY)
$42.1B
Argenex SE (ARGX)
$34.4B
BioNTech SE (BNTX)
$27.4B
Royalty Pharma (RPRX)
$20.3B
Biogen (BIIB)
$19.8B
Insmed (INSM)
$18.3B
Illumina (ILMN)
$15.8B
Genmab (GNMSF)
$14B
Genmab (GMAB)
$14B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.3B
Exelixis (EXEL)
$12.3B
BioMarin Pharmaceutical (BMRN)
$11.3B
QIAGEN (QGEN)
$10.8B
Ascendis Pharma (ASND)
$10.8B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$10.1B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.5B
Blueprint Medicines (BPMC)
$8.4B
Regencell Bioscience Holdings (RGC)
$8.2B
Roivant Sciences (ROIV)
$7.9B